ABBV-181

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:analysis ongoing
gptkbp:business_model approved by ethics committees
gptkbp:class gptkb:immunotherapy
gptkbp:clinical_trial gptkb:2016
Phase 1
multiple countries
overall response rate
pending publication
Phase 1 and beyond
NCT02830063
gptkbp:collaboration clinical research organizations
gptkbp:collaborations with academic institutions
with other pharmaceutical companies
gptkbp:developed_by gptkb:Abb_Vie
gptkbp:dosage_form based on clinical trial protocol
gptkbp:duration depends on response
gptkbp:efficacy_data preliminary results available
gptkbp:eligibility varies by trial
gptkbp:feedback collected during trials
gptkbp:funding provided by Abb Vie
gptkbp:future_prospects planned for combination therapies
https://www.w3.org/2000/01/rdf-schema#label ABBV-181
gptkbp:impact potential to improve outcomes
gptkbp:invention patented
gptkbp:investigator_initiated_trials may occur
gptkbp:is_monitored_by required during treatment
gptkbp:is_tested_for PD-L1 expression
gptkbp:mechanism_of_action immune checkpoint inhibition
blocks PD-1 receptor
gptkbp:potential_indications solid tumors
gptkbp:publication results published in journals
gptkbp:recruitment active in multiple sites
gptkbp:regulatory_compliance not yet approved
gptkbp:related_products submitted to FDA
under clinical investigation
gptkbp:related_to immune system
gptkbp:research_areas immuno-oncology
gptkbp:research_focus oncology
gptkbp:research_institutes various academic centers
gptkbp:research_output ongoing studies
gptkbp:research_updates provided to participants
gptkbp:route_of_administration intravenous
gptkbp:safety_features under investigation
gptkbp:safety_measures ongoing during trials
gptkbp:scientific_goals evaluate safety and efficacy
gptkbp:service_frequency every 2 weeks
gptkbp:side_effect immune-related adverse events
monitored during trials
gptkbp:sponsor gptkb:Abb_Vie
gptkbp:status investigational
gptkbp:target_audience patients with advanced cancer
gptkbp:targets gptkb:PD-1
gptkbp:treatment with chemotherapy
assessed by imaging
gptkbp:used_for gptkb:cancer_treatment
gptkbp:bfsParent gptkb:Upadacitinib
gptkbp:bfsLayer 6